blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2269069

EP2269069 - USE OF SYNTHETIC PEPTIDE DERIVED FROM ZEBRA PROTEIN FOR THE IN VIVO DIAGNOSIS OF THE EPSTEIN-BARR VIRUS (EBV) REACTIVATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.08.2012
Database last updated on 19.07.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
Université Joseph Fourier
621 Avenue Centrale Domaine Universitaire B.P. 53
38041 Grenoble Cedex 09 / FR
[2011/01]
Inventor(s)01 / DROUET, Emmanuel
7 Allée du Taillefer
F-38700 Corenc / FR
 [2011/01]
Representative(s)Grosset-Fournier, Chantal Catherine, et al
Grosset-Fournier & Demachy
54, rue Saint-Lazare
75009 Paris / FR
[N/P]
Former [2012/02]Grosset-Fournier, Chantal Catherine, et al
Grosset-Fournier & Demachy 54, rue Saint-Lazare
75009 Paris / FR
Former [2011/01]Mouget-Goniot, Claire, et al
Grosset-Fournier & Demachy 54, rue Saint-Lazare
75009 Paris / FR
Application number, filing date09719883.210.03.2009
[2011/01]
WO2009EP52798
Priority number, dateEP2008029022410.03.2008         Original published format: EP 08290224
[2011/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009112497
Date:17.09.2009
Language:EN
[2009/38]
Type: A1 Application with search report 
No.:EP2269069
Date:05.01.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 17.09.2009 takes the place of the publication of the European patent application.
[2011/01]
Type: B1 Patent specification 
No.:EP2269069
Date:26.10.2011
Language:EN
[2011/43]
Search report(s)International search report - published on:EP17.09.2009
ClassificationIPC:G01N33/569, C07K17/00
[2011/01]
CPC:
C07K17/00 (EP,US); G01N33/56994 (EP,US); G01N2333/05 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/01]
TitleGerman:VERWENDUNG EINES SYNTHETISCHEN PEPTIDS AUS DEM ZEBRA-PROTEIN FÜR DIE IN-VITRO DIAGNOSE VON EPPSTEIN-BARR-VIRUS (EBV)-REAKTIVIERUNG[2011/01]
English:USE OF SYNTHETIC PEPTIDE DERIVED FROM ZEBRA PROTEIN FOR THE IN VIVO DIAGNOSIS OF THE EPSTEIN-BARR VIRUS (EBV) REACTIVATION[2011/01]
French:UTILISATION DE PEPTIDE SYNTHÉTIQUE DÉRIVÉ DE LA PROTÉINE ZEBRA POUR LE DIAGNOSTIC IN VITRO DE LA RÉACTIVATION DU VIRUS D'EPSTEIN-BARR (EBV)[2011/01]
Entry into regional phase09.09.2010National basic fee paid 
09.09.2010Designation fee(s) paid 
09.09.2010Examination fee paid 
Examination procedure09.09.2010Amendment by applicant (claims and/or description)
09.09.2010Examination requested  [2011/01]
24.02.2011Despatch of a communication from the examining division (Time limit: M02)
25.03.2011Reply to a communication from the examining division
01.06.2011Communication of intention to grant the patent
05.09.2011Fee for grant paid
05.09.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.02.2011
Opposition(s)27.07.2012No opposition filed within time limit [2012/40]
Fees paidRenewal fee
07.03.2011Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.03.2009
AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
FI26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
MK26.10.2011
MT26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
TR26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
IE10.03.2012
LU10.03.2012
MC31.03.2012
[2014/34]
Former [2014/27]AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
FI26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
MK26.10.2011
MT26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
TR26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
IE10.03.2012
LU10.03.2012
MC31.03.2012
Former [2014/21]AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
FI26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
MK26.10.2011
MT26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
TR26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
IE10.03.2012
MC31.03.2012
Former [2013/35]AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
FI26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
MK26.10.2011
MT26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
IE10.03.2012
MC31.03.2012
Former [2013/29]AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
FI26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
MK26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
IE10.03.2012
MC31.03.2012
Former [2013/12]AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
MK26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
IE10.03.2012
MC31.03.2012
Former [2013/08]AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
IE10.03.2012
MC31.03.2012
Former [2013/07]AT26.10.2011
BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
MC31.03.2012
Former [2012/47]BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
MC31.03.2012
Former [2012/36]BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
RO26.10.2011
SE26.10.2011
SI26.10.2011
SK26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/35]BE26.10.2011
CY26.10.2011
CZ26.10.2011
DK26.10.2011
EE26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
SE26.10.2011
SI26.10.2011
BG26.01.2012
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/34]BE26.10.2011
CY26.10.2011
CZ26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
SE26.10.2011
SI26.10.2011
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/28]BE26.10.2011
CY26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
SE26.10.2011
SI26.10.2011
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/27]BE26.10.2011
HR26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
SE26.10.2011
SI26.10.2011
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/26]BE26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
PL26.10.2011
SE26.10.2011
SI26.10.2011
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/24]BE26.10.2011
LT26.10.2011
LV26.10.2011
NL26.10.2011
SE26.10.2011
SI26.10.2011
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/23]BE26.10.2011
LT26.10.2011
NL26.10.2011
NO26.01.2012
GR27.01.2012
IS26.02.2012
PT27.02.2012
Former [2012/21]BE26.10.2011
LT26.10.2011
NO26.01.2012
IS26.02.2012
Former [2012/20]LT26.10.2011
NO26.01.2012
Cited inInternational search[YDX]WO9621155  (PASTEUR INSTITUT [FR], et al) [YD] 1,5 * examples 1,2; claims 1-9 * [X] 11;
 [AD]WO0055622  (UNIV GRENOBLE 1 [FR], et al) [AD] * page 18, line 6 - line 20 *;
 [YDX]  - MARECHAL V ET AL., "Enzyme-linked immunosorbent assay for antibodies to ZEBRA, an Epstein-Barr trans-activator", RESEARCH VIROLOGY, (1993), vol. 144, no. 5, pages 397 - 404, XP022352696 [YD] 1-10 * the entire cocument, particularly abstract, page 398, figures 1-3 and "Discussion" * [X] 11

DOI:   http://dx.doi.org/10.1016/S0923-2516(06)80055-5
 [YDX]  - DROUET E ET AL., "High Epstein-Barr Virus Serum Load and Elevated Titers of Anti-ZEBRA Antibodies in Patients With EBV-Harboring Tumor Cells of Hodgkin's Disease", JOURNAL OF MEDICAL VIROLOGY, (1999), vol. 57, pages 383 - 389, XP002489204 [YD] 1-10 * page 384; figures 1,2; table 1 * [X] 11

DOI:   http://dx.doi.org/10.1002/(SICI)1096-9071(199904)57:4<383::AID-JMV10>3.0.CO;2-3
 [YDX]  - TOUGE C ET AL., "High incidence of elevated antibody titers to Epstein-Barr-virus in patients with uveitis", ARCHIVES OF VIROLOGY, (2006), vol. 151, pages 895 - 903, XP019378678 [YD] 1-10 * page 896 - page 898; figures 1-3; table 1 * [X] 11

DOI:   http://dx.doi.org/10.1007/s00705-005-0686-7
 [YDX]  - TEDESCHI R ET AL., "Activation of Maternal Epstein-Barr Virus Infection and Risk of Acute Leukemia in the Offspring", AMERICAN JOURNAL OF EPIDEMIOLOGY, (2006), vol. 165, no. 2, pages 134 - 137, XP002489206 [YD] 1-10 * abstract, page 135 * [X] 11

DOI:   http://dx.doi.org/10.1093/aje/kwj332
 [YDX]  - DARDARI R ET AL., "Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma", JOURNAL OF CLINICAL VIROLOGY, (200802), vol. 41, no. 2, pages 96 - 103, XP022503936 [YD] 1,5 * abstract * [X] 11

DOI:   http://dx.doi.org/10.1016/j.jcv.2007.09.010
 [YDX]  - DARDARI R ET AL, "Antibody Responses to Recombinant Epstein-Barr Virus Antigens in Nasopharyngeal Carcinoma Patients: Complementary Test of ZEBRA Protein and Early Antigens p54 and p138", JOURNAL OF CLINICAL MICROBIOLOGY, (2001), vol. 39, no. 9, pages 3164 - 3170, XP002489208 [YD] 1,5 * abstract, page 3165, tables 1-4 * [X] 11

DOI:   http://dx.doi.org/10.1128/JCM.39.9.3164-3170.2001
by applicantWO9621155
    - THORLEY-LAWSON DA, MIYASHITA EM, KHAN G., "Epstein-Barr virus and the B cell: that's all it takes", TRENDS MICROBIOL., (199605), vol. 4, no. 5, pages 204 - 8
    - SPECK SH, CHATILA T, FLEMINGTON E., "Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene", TRENDS MICROBIOL., (199710), vol. 5, no. 10, pages 399 - 405
    - FEEDERLE R, KOST M, BAUMANN M, JANZ A, DROUET E, HAMMERSCHMIDT W, DELECLUSE HJ., "The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators", EMBO J., (20000615), vol. 19, no. 12, pages 3080 - 9
    - HONG GK, GULLEY ML, FENG WH, DELECLUSE HJ, HOLLEY-GUTHRIE E, KENNEY SC., "Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model", J VIROL., (200511), vol. 79, no. 22, pages 13993 - 4003
    - MONTONE KT, HODINKA RL, SALHANY KE, LAVI E, ROSTAMI A, TOMASZEWSKI JE., "Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease", MOD PATHOL., (199606), vol. 9, no. 6, pages 621 - 30
    - MARECHAL V, MEYOHAS MC, JOAB I, GAHA S, GIOT JF, SERGEANT A, NICOLAS JC., "Enzyme-linked immunosorbent assay for antibodies to ZEBRA, an Epstein-Barr trans-activator", RES VIROL., (199309), vol. 144, no. 5, pages 397 - 404
    - JOAB I, TRIKI H, DE SAINT MARTIN J, PERRICAUDET M, NICOLAS JC., "Detection of anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus", J INFECT DIS., (199101), vol. 163, no. 1, pages 53 - 6
    - BROUSSET P, DROUET E, SCHLAIFER D, ICART J, PAYEN C, MEGGETTO F, MARCHOU B, MASSIP P, DELSOL G., "Epstein-Barr virus (EBV) replicative gene expression in tumour cells of AIDS- related non-Hodgkin's lymphoma in relation to CD4 cell number and antibody titres to EBV", AIDS, (199405), vol. 8, no. 5, pages 583 - 90
    - DARDARI R, MENEZES J, DROUET E, JOAB I, BENIDER A, BAKKALI H, KANOUNI L, JOUHADI H, BENJAAFAR N, GUEDDARI BE, "Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma", J CLIN VIROL., (20071119), vol. 41, no. 2, pages 96 - 103
    - DROUET E, BROUSSET P, FARES F, ICART J, VERNIOL C, MEGGETTO F, SCHLAIFER D, DESMORAT-COAT H, RIGAL-HUGUET F, NIVELEAU A, "High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease", J MED VIROL., (199904), vol. 57, no. 4, pages 383 - 9
    - TOUGE C, AGAWA H, SAIRENJI T, INOUE Y., "High incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis", ARCH VIROL., (200605), vol. 151, no. 5, pages 895 - 903
    - TEDESCHI R, BLOIGU A, OGMUNDSDOTTIR HM, MARUS A, DILLNER J, DEPAOLI P, GUDNADOTTIR M, KOSKELA P, PUKKALA E, LEHTINEN T, "Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring", AM J EPIDEMIOL., (20070115), vol. 165, no. 2, pages 134 - 7
    - DARDARI R, HINDERER W, LANG D, BENIDER A, EL GUEDDARI B, JOAB I, BENSLIMANE A, KHYATTI M., "Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138", J CLIN MICROBIOL., (200109), vol. 39, no. 9, pages 3164 - 70
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.